Boehringer Ingelheim Press Releases 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 10, 2016 Category: Research Source Type: news
Results of Phase III study of volasertib for the treatment of acute myeloid leukemia presented at European Hematology Association Annual Meeting
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 10, 2016 Category: Research Source Type: news
Boehringer Ingelheim and Harvard scientists establish a research alliance to find novel treatments for severe fibrotic diseases
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 8, 2016 Category: Research Source Type: news
Boehringer Ingelheim and HealthPrize Partner to Launch New Support Program for People Treating COPD With SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray
People living with chronic obstructive pulmonary disease (COPD) can earn rewards for tracking medication use and learning more about COPD (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 7, 2016 Category: Research Source Type: news
Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 5, 2016 Category: Research Source Type: news
Boehringer Ingelheim launches ambitious ELUXA trial program to broadly investigate promising lung cancer compound olmutinib
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - June 1, 2016 Category: Research Source Type: news
U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes
New formulation of medicines that helps lower blood sugar in type 2 diabetes can be taken once a day (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - May 30, 2016 Category: Research Source Type: news
Boehringer Ingelheim Launches “Conoce a Don Francisco” Sweepstakes
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - May 18, 2016 Category: Research Source Type: news
New Presentations at ATS 2016 Reinforce OFEV® (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with IPF
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - May 15, 2016 Category: Research Source Type: news
Boehringer Ingelheim has a successful 2015 financial year
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - April 18, 2016 Category: Research Source Type: news
Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure
• New studies will evaluate the effect of JARDIANCE for the treatment of chronic heart failure • There are approximately 26 million people worldwide, and 5.7 million people in the U.S., suffering from chronic heart failure• The studies build on results from the landmark EMPA-REG OUTCOME® trial (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - April 18, 2016 Category: Research Source Type: news
FDA approves Gilotrif® (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung
• Approval provides a new second-line treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing about 20-30% of NSCLC cases • Approval is based on results of the LUX-Lung 8 study, which showed significantly improved overall survival and progression-free survival compared to Tarceva® (erlotinib) in patients with squamous cell carcinoma of the lung • Gilotrif is already approved in more than 60 countries for the treatment of patients with distinct types of EGFR mutation-positive NSCLC (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - April 14, 2016 Category: Research Source Type: news
Head-to-head study demonstrating Gilotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology
• LUX-Lung 7 trial showed afatinib significantly reduced the risk of lung cancer progression and treatment failure as well as increased overall response rate compared to gefitinib without compromising overall health-related quality of life, safety and tolerability • Results provide oncologists who treat patients with EGFR mutation-positive lung cancer with important information for clinical practice (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - April 12, 2016 Category: Research Source Type: news
Lancet Publication: New Analysis Demonstrates Only Small Minority of Severe/Very Severe COPD Patients May Benefit from Adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) + LABA Therapy
• New post-hoc analysis shows routine eosinophil blood test could help identify the small minority of severe/very severe patients who may benefit from addition of ICS* • Only 20 percent of patients in WISDOM† study benefited from addition of ICS on top of SPIRIVA® HANDIHALER®‡ and a LABA§ with regards to exacerbation risk reduction • The data analysis, published in Lancet Respiratory Medicine, adds to current debate about appropriate selection of patients for ICS treatment in chronic obstructive pulmonary disease (COPD) (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - April 7, 2016 Category: Research Source Type: news
New Survey: People Living with Asthma Believe it is Controlled, But Persistent Symptoms and Limits to Everyday Activities Tell a Different Story
• Surveyed healthcare providers expect well-controlled asthma patients should experience no limits to everyday activities and fewer asthma symptoms (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - April 6, 2016 Category: Research Source Type: news
